Advertisement
Research Article

Clinical Significance of sIL-2R Levels in B-Cell Lymphomas

  • Noriaki Yoshida mail,

    nyoshida@aichi-cc.jp (NY); sakira@fmu.ac.jp (AS)

    Affiliations: Department of Hematology and Oncology, Research Institute Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan, Department of Cancer Genetics, Nagoya University Graduate School of Medicine at Aichi Cancer Center Research Institute, Nagoya, Japan

    X
  • Miyo Oda,

    Affiliation: Department of Anatomical Pathology, Hiroshima University, Hiroshima, Japan

    X
  • Yoshiaki Kuroda,

    Affiliation: Department of Hematology and Oncology, Research Institute Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

    X
  • Yuta Katayama,

    Affiliation: Department of Internal Medicine, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan

    X
  • Yoshiko Okikawa,

    Affiliation: Department of Hematology, National Hospital Organization Kure Medical Center, Kure, Japan

    X
  • Taro Masunari,

    Affiliation: Department of Hematology, Chugoku Central Hospital, Fukuyama, Japan

    X
  • Megumu Fujiwara,

    Affiliation: Department of Pathology, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan

    X
  • Takashi Nishisaka,

    Affiliation: Department of Laboratory Pathology, Hiroshima Prefecture Hospital, Hiroshima, Japan

    X
  • Naomi Sasaki,

    Affiliation: Department of Pathology, Kure Kyosai Hospital, Kure, Japan

    X
  • Yoshito Sadahira,

    Affiliation: Department of Pathology, Kawasaki Medical School, Kurashiki, Japan

    X
  • Keichiro Mihara,

    Affiliation: Department of Hematology and Oncology, Research Institute Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

    X
  • Hideki Asaoku,

    Affiliation: Department of Internal Medicine, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan

    X
  • Hirotaka Matsui,

    Affiliation: Department of Molecular Oncology & Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

    X
  • Masao Seto,

    Affiliations: Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan, Department of Cancer Genetics, Nagoya University Graduate School of Medicine at Aichi Cancer Center Research Institute, Nagoya, Japan

    X
  • Akiro Kimura,

    Affiliations: Department of Hematology and Oncology, Research Institute Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Department of Laboratory medicine, Kure Kyosai Hospital, Kure, Japan

    X
  • Koji Arihiro,

    Affiliation: Department of Anatomical Pathology, Hiroshima University, Hiroshima, Japan

    X
  • Akira Sakai mail

    nyoshida@aichi-cc.jp (NY); sakira@fmu.ac.jp (AS)

    Affiliations: Department of Hematology and Oncology, Research Institute Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Department of Radiation Life Science, Fukushima Medical University, Fukushima, Japan

    X
  • Published: November 13, 2013
  • DOI: 10.1371/journal.pone.0078730

Reader Comments (0)

Post a new comment on this article